Status:
COMPLETED
Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma
Lead Sponsor:
Cooperative Study Group A for Hematology
Conditions:
Chronic Lymphocytic Leukemia
Lymphoma
Eligibility:
All Genders
15-65 years
Phase:
PHASE2
Brief Summary
Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine and Melphalan Conditioning Regimen for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma
Detailed Description
Treatment plan * Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2. * F...
Eligibility Criteria
Inclusion
- Patients must be 15 years of age or older and 65 years of age or younger
- Patients with CLL, lymphoma, or multiple myeloma will be included in this study
- No prior anti-cancer treatment should be done within 30 days.
- Informed consent should be given.
- Patients should have an HLA-identical or single HLA-locus mismatched donor.
- Karnofsky performance scale should be 50 or over (see Appendix I).
Exclusion
- Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the stem cell transplant treatment unlike, and making informed consent impossible.
- Patients with high serum creatinine level will be excluded.
- Patients should have uncontrolled infection.
- No major anticipated illness or organ failure incompatible with survival from stem cell transplant.
- Serum bilirubin less than or equal to 4.0 mg/dL.
Key Trial Info
Start Date :
July 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00772811
Start Date
July 1 2001
End Date
December 1 2010
Last Update
February 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736